title: Tissue distribution of 2-3 and 2-6 sialyl Lewis A antigens and significance of the ratio of two antigens for the differential diagnosis of malignant and benign disorders of the digestive tract.
abstract: The authors investigated the tissue distribution of two kinds of sialylated derivatives of Lewis A (Le(a)) antigen in patients with cancers of the digestive system using specific monoclonal antibodies, and evaluated the significance of determining the 2-3 and 2-6 sialylated Le(a) antigen levels for the diagnosis of cancer. In most specimens from patients with cancers of the pancreas, biliary tract, stomach, and colon, the 2-3 sialylated Le(a) antigen was strongly expressed in cancer cells. However, 2-6 sialylated Le(a) antigen was less frequently expressed in cancer cells. The former is therefore more specific to cancer than the latter. Also, the serum level of the 2-3 sialylated Le(a) antigen was significantly higher than that of the 2-6 counterpart in patients with cancers of pancreas, biliary tract, stomach, and colon. The resulting ratio of serum 2-3/2-6 sialylated Le(a) antigens was frequently high in patients with malignancy and was low in patients with benign disorders of these digestive organs. Therefore, the 2-3/2-6 sialylated Le(a) antigen ratio is a useful for the differential diagnosis of malignant disorders in these organs. However, liver disorders were found to be exceptional in that both antigens were mostly absent in hepatocellular carcinoma (HCC) cells in immunohistologic examination, as well as in nonmalignant parenchymal liver cells. Only the epithelial cells of the intrahepatic bile ducts expressed the 2-6 sialylated Le(a) antigen strongly, and expressed the 2-3 sialylated Le(a) antigen moderately. The levels of both antigens were sometimes high in patients with liver disorders, but the ratio always remained low in patients with HCC as well as benign liver disorders such as cirrhosis or chronic hepatitis. The sialylated Le(a) antigens, which sometimes accumulate in the sera of patients with HCC, were concluded to originate from the epithelial cells of the proliferating small bile ducts, and those serum antigens cannot be considered as evidence for the presence of liver cancer cells.
authors.affiliation: Department of Laboratory Medicine and Clinical Science, Kyoto University, School of Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Itai
authors.forename: J
authors.initials: J
authors.lastname: Nishikata
authors.forename: T
authors.initials: T
authors.lastname: Yoneda
authors.forename: K
authors.initials: K
authors.lastname: Ohmori
authors.forename: H
authors.initials: H
authors.lastname: Yamabe
authors.forename: S
authors.initials: S
authors.lastname: Arii
authors.forename: T
authors.initials: T
authors.lastname: Tobe
authors.forename: R
authors.initials: R
authors.lastname: Kannagi
mesh_terms: D000911:Antibodies, Monoclonal / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis*; D001661:Biliary Tract Neoplasms / Q000175:diagnosis / Q000276:immunology; D003937:Diagnosis, Differential; D004066:Digestive System Diseases / Q000175:diagnosis* / Q000276:immunology; D004067:Digestive System Neoplasms / Q000175:diagnosis* / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000175:diagnosis / Q000276:immunology; D012016:Reference Values
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm